AstraZeneca is plucking another antisense drug out of Ionis’ prolific pipeline. Paying $200 million in cash, AstraZeneca has inked a development and commercialization deal around eplontersen — the…
After trial investigators flagged a drop in immune cell counts that an external committee determined was related to treatment last month, Merck has been pausing HIV-related Phase II and III trials…
Metis Therapeutics launched with $86 million to test its lead candidate in an early-2022 clinical trial and to bankroll the in-licensing of new assets. The small-molecule and RNA therapeutics biotech…
Are the foundations of Merck’s broad HIV development program crumbling? Having already paused combination work in response to a red flag, Merck has now temporarily stopped enrollment in phase 3…
GlaxoSmithKline and partner Medicago have seen some strong efficacy numbers against current dominating SARS-CoV-02 strain delta, but the emergence of omicron will likely upset these numbers.
With multiple mid- and late-stage failures of its only clinical-stage compound, Corbus Pharmaceuticals is attempting to move forward with earlier-stage assets it in-licensed this summer. So the…
The artificial intelligence-powered drug designer Recursion signed on to a wide-ranging collaboration with Roche and its Genentech division. Starting with a hefty $150 million upfront payment, the…
Apple Tree Partners has picked its first U.K.-based venture to launch: Adendra Therapeutics, an immunotherapy company focused on dendritic cell biology to treat cancers and autoimmune diseases.…
In what has become an annual tradition for Freenome, the developer of a liquid biopsy platform for early cancer detection closed yet another venture capital megaround, sending its total fundraising…
With GlaxoSmithKline, Pfizer and others in the running, Johnson & Johnson may need excellent data to capture the RSV vaccine market. The Big Pharma gave a further show of its credentials on Tuesday by…
